Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Tiens Biotech Group (USA) (TBV)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for TBV as compared to
Top Competitors
Drug Related Products.
Drug Related Products
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS (
See all
)
Revenue
►
66.8M
AVG
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
66.8M
AVG
EBITDA
►
28.8M
HIGH
Net Income
►
25.9M
HIGH
Revenue Growth
►
-7.2%
AVG
Net Income Growth
►
-2.9%
HIGH
Operating Margin
►
42%
VERY HIGH
Net Margin
►
39.4%
VERY HIGH
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
0.320
AVG
Current Ratio
►
2.54
AVG
Quick Ratio
►
2.36
AVG
Interest Coverage Ratio
►
131
HIGH
Book Value Per Share
►
2.39
Cash Per Share
►
0.469
Loading...
STOCK SUMMARY
Open
Day Range
-
52 Week Range
-
Volume
Avg Volume (3 mo)
Shares Outstanding
Market Cap
VALUATION
Price to Earnings (P/E)
►
12.8
LOW
Price to Book (P/B)
►
1.98
AVG
Price to Sales (P/S)
►
5.05
HIGH
Return on Assets (ROA)
►
12.3%
HIGH
Return on Equity (ROE)
►
16.5%
AVG
EV/EBITDA
►
13.0
AVG
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
0%
Net Insider Buying 1yr
0%
Held by insiders
46.9%
Held by institutions
0%